Results 121 to 130 of about 853 (171)

Assessment of the molecular identification algorithm and its impact on antifungal susceptibilities against clinical <i>Fusarium</i> isolates: a multicentre study in Taiwan, 2011-2023. [PDF]

JAC Antimicrob Resist
Chen PY, Wu CJ, Wu UI, Liu WD, Chen YC.
europepmc   +1 more source

Multisystem <i>Lomentospora prolificans</i> progression on fosmanogepix despite <i>in vitro</i> activity: a call for expanding clinical research on novel antifungals. [PDF]

ASM Case Rep
Cooper RA, Arif S, Baker AW, Wiederhold NP, Sarantopoulos S, Iftikhar M, Stanly K, Collis B, Ni B, Sim BZ, Perfect JR, Alexander BD, Heldman MR.   +12 more
europepmc   +1 more source

New preparations in systemic fungal infections [PDF]

Introducere Infecțiile fungice sistemice (invazive) reprezintă o problemă medicală și de sănătate publică majoră în ultimele două decenii. S-a estimat că, la nivel global, 1-1,2 miliarde de persoane sunt afectate de fungi, cu aproximativ 1,5 milioane ...
Bacinschi, Nicolae, Catcov, Carolina, Spînosu, Galina   +2 more
core  

Successful Control of Refractory <i>Coccidioides</i> Meningitis With MAT2203. [PDF]

Open Forum Infect Dis
Mehta SR, Johns S, Matkovits T, Ferguson J, Fierer J.   +4 more
europepmc   +1 more source

Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant <i>Lomentospora prolificans</i> infection in a child. [PDF]

Antimicrob Agents Chemother
Wiederhold NP.
europepmc   +1 more source

Successful use of olorofim for the treatment of <i>Lomentospora prolificans</i> knee tendonitis, synovitis, and concomitant osteomyelitis in an immunocompetent child. [PDF]

Antimicrob Agents Chemother
Fortini M, Jones TW, Grams TR, Mehra S.
europepmc   +1 more source

A quiet but growing threat: Global perspectives on antifungal resistance and future therapeutic approaches. [PDF]

Indian J Pharmacol
Gurajala S, Challapilla M.
europepmc   +1 more source

Update 2016-2018 of the nationwide Danish fungaemia surveillance study:epidemiologic changes in a 15-year perspective [PDF]

, 2019
Antsupova, V. S., Arendrup, M. C., Astvad, K. M. T., Datcu, R., Dzajic, Esad, Gertsen, J. B., Hare, R., Johansen, H.K., Jørgensen, K. M., Knudsen, I.J.D., Kristensen, L., Møller, J. K., Risum, M., Rosenvinge, F. S., Røder, B. L., Schønheyder, Henrik   +15 more
core   +1 more source

Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective. [PDF]

Antimicrob Agents Chemother
Walsh TJ, Coleman CI, Blissett R, Prawitz T, Bonetti G, Aguiar M, Bresnik M, Lovelace B.   +7 more
europepmc   +1 more source

Faculty Opinions recommendation of The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2021
openaire   +2 more sources